These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 2826591

  • 1. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A, Merigan TC.
    J Immunol; 1988 Jan 01; 140(1):294-9. PubMed ID: 2826591
    [Abstract] [Full Text] [Related]

  • 2. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection.
    Weinberg A, Basham TY, Merigan TC.
    J Immunol; 1986 Nov 15; 137(10):3310-7. PubMed ID: 3021853
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR.
    J Infect Dis; 2003 Feb 15; 187(4):542-9. PubMed ID: 12599070
    [Abstract] [Full Text] [Related]

  • 6. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
    Simms JR, Heath AW, Jennings R.
    J Infect Dis; 2000 Apr 15; 181(4):1240-8. PubMed ID: 10762560
    [Abstract] [Full Text] [Related]

  • 7. Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.
    Weinberg A, Konrad M, Merigan TC.
    J Virol; 1987 Jul 15; 61(7):2120-7. PubMed ID: 3035213
    [Abstract] [Full Text] [Related]

  • 8. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB.
    J Infect Dis; 2005 Dec 15; 192(12):2117-23. PubMed ID: 16288376
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Herpes simplex virus vaccine studies: from past to present].
    Us D.
    Mikrobiyol Bul; 2006 Oct 15; 40(4):413-33. PubMed ID: 17205702
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F.
    FEMS Immunol Med Microbiol; 2008 Oct 15; 54(1):18-26. PubMed ID: 18647350
    [Abstract] [Full Text] [Related]

  • 13. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
    Cui FD, Asada H, Jin ML, Kishida T, Shin-Ya M, Nakaya T, Kita M, Ishii M, Iwai M, Okanoue T, Imanishi J, Mazda O.
    Gene Ther; 2005 Jan 15; 12(2):160-8. PubMed ID: 15470476
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
    Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL.
    Virology; 1998 Dec 05; 252(1):200-9. PubMed ID: 9875329
    [Abstract] [Full Text] [Related]

  • 17. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L, Dundarov S, Andonov P, Bakalov B, Dundarova D, Brodvarova I.
    Acta Virol; 1986 Sep 05; 30(5):402-10. PubMed ID: 2878588
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M, Mayumi-Aono A, Asakawa N, Kuroda S, Hinuma S, Fujisawa Y.
    Vaccine; 1993 Sep 05; 11(6):629-36. PubMed ID: 8391739
    [Abstract] [Full Text] [Related]

  • 19. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.
    Scriba M.
    Med Microbiol Immunol; 1978 Nov 17; 166(1-4):63-9. PubMed ID: 214688
    [Abstract] [Full Text] [Related]

  • 20. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S, Rouse BT.
    J Immunol; 1987 May 15; 138(10):3431-7. PubMed ID: 3033075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.